dPCR works by partitioning (diluting) a DNA sample into many individual, parallel PCR reactions, where some of these reactions contain the target molecule while others do not. Highly specific fluorescent probes bind to the amplicons differentiating between alleles. The number of droplets that light up with the same fluorescent signature provides an accurate measure of the number of target molecules in the original sample. “Oncology drives the digital PCR field,” says Alexandra Martin, Ph.D., sales application specialist, Stilla Technologies (Paris, France). “dPCR is essential for detecting rare genetic variants present in very small quantities amongst a large number of wild-type copies. Specific, consistent detection of cancer alleles in blood samples would revolutionize diagnosis and personalized cancer treatment.
Source : Genetic Engineering News